Bibliography
- KRAPCHO AP, MARESCH MJ, HACKER MP et al.: Anthracene,-9,10-diones and aza bioisosteres as antitumor agents. Carr. Med. Chem. (1995) 2:803–824.
- ••A review of nitrogen atom substitution on the anthracene-dione ring system and the antitumour properties of the resulting 'aza' derivatives.
- BORCHMANN P, KNIPPERTZ R, SCHNELL R et al.: Pharma- cokinetics, and clinical results of the new aza- anthra-cenedione Bbr2778 in patients with advanced nonhodgkin, lymphomas. Blood (1999) 94:4364
- •A poster describing recent clinical and pharmacokinetic findings of BbR2778.
- FAIVRE S, BORCHMANN P, JODRELL D et al.: Bbr2778 a new, anthracenedione analogue with no preclinical cardiac toxicity: results from 3 phase I studies. Clin. Cancer Res. (1999) 5:329
- •A poster describing recent clinical and pharmacokinetic findings of BbR2778.
- DEISABELLA P, PALUMBO M, SISSI C et al.: Physico- chemical, properties, cytotoxic activity and topoisomerase II inhibition of 2,3-diaza-anthracenediones. Biochem. Pharmacol. (1997) 53:161–169.
- WANG HK, MORRISNATSCHKE SL, LEE KH: Recent advances, in the discovery and development of topoisomerase inhibitors as antitumor agents. Med. Res. Rev. (1997) 17:367–425.
- ••A recent review of topoisomerase II inhibitors as antitumouragents.
- POMMIER Y: DNA topoisomerase II inhibitors. In: Cancer, Therapeutics. Teicher BA (Ed.), Humana Press Inc., Totowa, (1997) :153–174.
- ••A recent review of topoisomerase II inhibitors as antitumouragents.